Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.
Authors: Goldstein AM,  Chan M,  Harland M,  Gillanders EM,  Hayward NK,  Avril MF,  Azizi E,  Bianchi-Scarra G,  Bishop DT,  Bressac-de Paillerets B,  Bruno W,  Calista D,  Cannon Albright LA,  Demenais F,  Elder DE,  Ghiorzo P,  Gruis NA,  Hansson J,  Hogg D,  Holland EA,  Kanetsky PA,  Kefford RF,  Landi MT,  Lang J,  Leachman SA,  Mackie RM,  Magnusson V,  Mann GJ,  Niendorf K,  Newton Bishop J,  Palmer JM,  Puig S,  Puig-Butille JA,  de Snoo FA,  Stark M,  Tsao H,  Tucker MA,  Whitaker L,  Yakobson E,  Melanoma Genetics Consortium (GenoMEL)
Journal: Cancer Res
Date: 2006 Oct 15
Branches: ITEB
PubMed ID: 17047042
PMC ID: not available
Abstract: GenoMEL, comprising major familial melanoma research groups from North America, Europe, Asia, and Australia has created the largest familial melanoma sample yet available to characterize mutations in the high-risk melanoma susceptibility genes CDKN2A/alternate reading frames (ARF), which encodes p16 and p14ARF, and CDK4 and to evaluate their relationship with pancreatic cancer (PC), neural system tumors (NST), and uveal melanoma (UM). This study included 466 families (2,137 patients) with at least three melanoma patients from 17 GenoMEL centers. Overall, 41% (n = 190) of families had mutations; most involved p16 (n = 178). Mutations in CDK4 (n = 5) and ARF (n = 7) occurred at similar frequencies (2-3%). There were striking differences in mutations across geographic locales. The proportion of families with the most frequent founder mutation(s) of each locale differed significantly across the seven regions (P = 0.0009). Single founder CDKN2A mutations were predominant in Sweden (p.R112_L113insR, 92% of family's mutations) and the Netherlands (c.225_243del19, 90% of family's mutations). France, Spain, and Italy had the same most frequent mutation (p.G101W). Similarly, Australia and United Kingdom had the same most common mutations (p.M53I, c.IVS2-105A>G, p.R24P, and p.L32P). As reported previously, there was a strong association between PC and CDKN2A mutations (P < 0.0001). This relationship differed by mutation. In contrast, there was little evidence for an association between CDKN2A mutations and NST (P = 0.52) or UM (P = 0.25). There was a marginally significant association between NST and ARF (P = 0.05). However, this particular evaluation had low power and requires confirmation. This GenoMEL study provides the most extensive characterization of mutations in high-risk melanoma susceptibility genes in families with three or more melanoma patients yet available.